Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Increase in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, a growth of 269.5% from the September 15th total of 10,500 shares. Based on an average daily trading volume, of 139,900 shares, the short-interest ratio is presently 0.3 days.

Astellas Pharma Trading Up 1.6 %

ALPMY traded up $0.19 during mid-day trading on Thursday, reaching $11.84. The stock had a trading volume of 139,376 shares, compared to its average volume of 247,608. The stock has a market capitalization of $21.43 billion, a P/E ratio of 169.14 and a beta of 0.37. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90. The firm's fifty day simple moving average is $11.94 and its two-hundred day simple moving average is $10.71. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $14.03.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.24 EPS for the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. The firm had revenue of $3.03 billion for the quarter. On average, equities analysts predict that Astellas Pharma will post 0.54 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.